Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleOncology

Phase I Study of 99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer

Olga Bragina, Emma von Witting, Javad Garousi, Roman Zelchan, Mattias Sandström, Anna Orlova, Anna Medvedeva, Artem Doroshenko, Anzhelika Vorobyeva, Sarah Lindbo, Jesper Borin, Natalya Tarabanovskaya, Jens Sörensen, Sophia Hober, Vladimir Chernov and Vladimir Tolmachev
Journal of Nuclear Medicine April 2021, 62 (4) 493-499; DOI: https://doi.org/10.2967/jnumed.120.248799
Olga Bragina
1Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma von Witting
3Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology, and Health, KTH Royal Institute of Technology, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javad Garousi
4Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roman Zelchan
1Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mattias Sandström
5Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
6Medical Physics, Uppsala University Hospital, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Orlova
2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia
7Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Medvedeva
1Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Artem Doroshenko
8Department of General Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anzhelika Vorobyeva
2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia
4Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Lindbo
3Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology, and Health, KTH Royal Institute of Technology, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesper Borin
3Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology, and Health, KTH Royal Institute of Technology, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalya Tarabanovskaya
8Department of General Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jens Sörensen
5Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophia Hober
3Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology, and Health, KTH Royal Institute of Technology, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimir Chernov
1Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vladimir Tolmachev
2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia
4Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 62 no. 4 493-499
DOI 
https://doi.org/10.2967/jnumed.120.248799
PubMed 
32817142

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication May 1, 2020
  • Accepted for publication July 3, 2020
  • Published online March 29, 2021.

Article Versions

  • previous version (August 17, 2020 - 05:27).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Olga Bragina1,2,
  2. Emma von Witting3,
  3. Javad Garousi4,
  4. Roman Zelchan1,2,
  5. Mattias Sandström5,6,
  6. Anna Orlova2,7,
  7. Anna Medvedeva1,
  8. Artem Doroshenko8,
  9. Anzhelika Vorobyeva2,4,
  10. Sarah Lindbo3,
  11. Jesper Borin3,
  12. Natalya Tarabanovskaya8,
  13. Jens Sörensen5,
  14. Sophia Hober3,
  15. Vladimir Chernov1,2 and
  16. Vladimir Tolmachev2,4
  1. 1Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
  2. 2Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk, Russia
  3. 3Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology, and Health, KTH Royal Institute of Technology, Stockholm, Sweden
  4. 4Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden
  5. 5Radiology and Nuclear Medicine, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
  6. 6Medical Physics, Uppsala University Hospital, Uppsala, Sweden
  7. 7Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden; and
  8. 8Department of General Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia
  1. For correspondence or reprints contact: Vladimir Tolmachev, Department of Immunology, Genetics, and Pathology, Uppsala University, SE-75181, Uppsala, Sweden. E-mail: vladimir.tolmachev{at}igp.uu.se
View Full Text

Statistics from Altmetric.com

Cited By...

  • 42 Citations
  • 48 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Molecular and functional imaging in cancer-targeted therapy: current applications and future directions
    Jing-Wen Bai, Si-Qi Qiu, Guo-Jun Zhang
    Signal Transduction and Targeted Therapy 2023 8 1
  • Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy
    Jakob Lindberg, Johan Nilvebrant, Per-Åke Nygren, Fredrik Lehmann
    Molecules 2021 26 19
  • Photothermal Therapy with HER2-Targeted Silver Nanoparticles Leading to Cancer Remission
    Victoria O. Shipunova, Mariia M. Belova, Polina A. Kotelnikova, Olga N. Shilova, Aziz B. Mirkasymov, Natalia V. Danilova, Elena N. Komedchikova, Rachela Popovtzer, Sergey M. Deyev, Maxim P. Nikitin
    Pharmaceutics 2022 14 5
  • Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer
    Olga Bragina, Vladimir Chernov, Alexey Schulga, Elena Konovalova, Eugeniy Garbukov, Anzhelika Vorobyeva, Anna Orlova, Liubov Tashireva, Jens Sörensen, Roman Zelchan, Anna Medvedeva, Sergey Deyev, Vladimir Tolmachev
    Journal of Nuclear Medicine 2022 63 4
  • Targeted nuclear medicine. Seek and destroy
    V. M. Tolmachev, V. I. Chernov, S. M. Deyev
    Russian Chemical Reviews 2022 91 3
  • Artificial Scaffold PolypeptidesAs an Efficient Tool for the Targeted Delivery of Nanostructures In Vitro and In Vivo
    Victoria O. Shipunova, Sergey M. Deyev
    Acta Naturae 2022 14 1
  • PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology
    Sara S. Rinne, Anna Orlova, Vladimir Tolmachev
    International Journal of Molecular Sciences 2021 22 7
  • Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors
    Vladimir Chernov, Anastasiya Rybina, Roman Zelchan, Anna Medvedeva, Olga Bragina, Nadejda Lushnikova, Artem Doroshenko, Evgeniy Usynin, Liubov Tashireva, Sergey Vtorushin, Ayman Abouzayed, Sara S. Rinne, Jens Sörensen, Vladimir Tolmachev, Anna Orlova
    Cancers 2023 15 6
  • Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
    Maryam Oroujeni, Sara S. Rinne, Anzhelika Vorobyeva, Annika Loftenius, Joachim Feldwisch, Per Jonasson, Vladimir Chernov, Anna Orlova, Fredrik Y. Frejd, Vladimir Tolmachev
    International Journal of Molecular Sciences 2021 22 5
  • Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle
    Javad Garousi, Emma von Witting, Jesper Borin, Anzhelika Vorobyeva, Mohamed Altai, Olga Vorontsova, Mark W. Konijnenberg, Maryam Oroujeni, Anna Orlova, Vladimir Tolmachev, Sophia Hober
    Biomaterials 2021 266

Article usage

Article usage: August 2020 to May 2025

AbstractFullPdf
Aug 2020387025
Sep 2020314012
Oct 202016207
Nov 2020158029
Dec 2020127011
Jan 202113306
Feb 2021159017
Mar 20213811061
Apr 202111324046
May 20214681435
Jun 20212111034
Jul 20212271032
Aug 2021137316
Sep 2021132924
Oct 2021785048
Nov 2021658085
Dec 2021665647
Jan 2022585954
Feb 2022345431
Mar 2022336146
Apr 2022346056
May 2022314626
Jun 2022335917
Jul 2022425014
Aug 2022364120
Sep 2022122822
Oct 2022184037
Nov 2022193024
Dec 2022173712
Jan 2023163417
Feb 2023224624
Mar 2023194028
Apr 202371312
May 2023172121
Jun 2023133722
Jul 202382320
Aug 2023142421
Sep 2023232213
Oct 2023172915
Nov 2023113219
Dec 2023255626
Jan 2024303720
Feb 2024242814
Mar 202493355
Apr 2024165040
May 2024275527
Jun 202494625
Jul 2024115931
Aug 2024247032
Sep 2024185121
Oct 2024165121
Nov 202495526
Dec 2024133426
Jan 202554524
Feb 20251810123
Mar 2025167834
Apr 2025266858
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (4)
Journal of Nuclear Medicine
Vol. 62, Issue 4
April 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Phase I Study of 99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Phase I Study of 99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer
Olga Bragina, Emma von Witting, Javad Garousi, Roman Zelchan, Mattias Sandström, Anna Orlova, Anna Medvedeva, Artem Doroshenko, Anzhelika Vorobyeva, Sarah Lindbo, Jesper Borin, Natalya Tarabanovskaya, Jens Sörensen, Sophia Hober, Vladimir Chernov, Vladimir Tolmachev
Journal of Nuclear Medicine Apr 2021, 62 (4) 493-499; DOI: 10.2967/jnumed.120.248799

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Phase I Study of 99mTc-ADAPT6, a Scaffold Protein–Based Probe for Visualization of HER2 Expression in Breast Cancer
Olga Bragina, Emma von Witting, Javad Garousi, Roman Zelchan, Mattias Sandström, Anna Orlova, Anna Medvedeva, Artem Doroshenko, Anzhelika Vorobyeva, Sarah Lindbo, Jesper Borin, Natalya Tarabanovskaya, Jens Sörensen, Sophia Hober, Vladimir Chernov, Vladimir Tolmachev
Journal of Nuclear Medicine Apr 2021, 62 (4) 493-499; DOI: 10.2967/jnumed.120.248799
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Phase I Trial of 99mTc-(HE)3-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer
  • Google Scholar

More in this TOC Section

Oncology

  • Role of PET/CT in the management of multiple myeloma
  • FDG-PET/CT and NaF-PET/CT in the diagnosis and assessment of radiation therapy-induced vascular complications in patients with head and neck cancer
  • 18F-FDG PET/CT manifestations of three Cases of Female Desmoplastic Small Round Cell Tumor
Show more Oncology

Clinical

  • Role of PET/CT in the management of multiple myeloma
  • FDG-PET/CT and NaF-PET/CT in the diagnosis and assessment of radiation therapy-induced vascular complications in patients with head and neck cancer
  • 18F-FDG PET/CT manifestations of three Cases of Female Desmoplastic Small Round Cell Tumor
Show more Clinical

Similar Articles

Keywords

  • HER2
  • ADAPT6
  • 99mTc
  • SPECT
  • phase I
SNMMI

© 2025 SNMMI

Powered by HighWire